Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study

Toh, Zheng Quan; Russell, Fiona M.; Reyburn, Rita; Fong, James; Tuivaga, Evelyn; Ratu, Tupou; Nguyen, Cattram; Devi, Rachel; Kama, Mike; Matanitobua, Silivia; Tabrizi, Sepehr N.; Garland, Suzanne M.; Sinha, Rohit Anthony; Frazer, Ian H.; Tikoduadua, Lisi; Kado, Joseph; Rafai, Eric; Mulholland, E. Kim; Licciardi, Paul V.

doi:10.1093/cid/ciw865

Cited by 28 publications

(52 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The secondary analyses were the comparison of the NAb GMTs one month post-2vHPV between girls who received zero, one or two doses and girls who received three doses. We also stratified the girls in each dosage group by ethnicity and compared their NAb GMTs based on our previous findings that vaccine-type NAb titres differed by ethnicity [22]. Within the two-dose group, we also stratified the girls into those who received two doses <6 months or ≥6 months apart, and compared their NAb GMTs before and one month after 2vHPV.…”

Section: Discussionmentioning

confidence: 99%

“…The details of the study design, enrolled participants as well as study procedures have been described previously [22]. Briefly, a cohort study was conducted in Fiji between February and March 2015.…”

Section: Study Design Procedures and Participantsmentioning

confidence: 99%

“…Since 2015, two doses of HPV vaccine given six months apart has been recommended by the World Health Organization for girls under 15 years old [20]. Furthermore, there is promising observational data on the immunogenicity and efficacy of single-dose HPV vaccine schedules against vaccine-type HPV infection, and data from randomised controlled trials are anticipated [11,[21][22][23]. The question of whether reduced-dose schedules generate similar durable NAb to potentially cross-reactive HPV genotypes 31, 33, 45, 52 and 58 as the three-dose schedule is unknown.…”

Section: Introductionmentioning

confidence: 99%

“…We performed a cohort study in Fiji to examine the immunogenicity of reduced-dose 4vHPV vaccine schedules in girls previously unimmunised or immunised with one, two or three doses of 4vHPV. The vaccine genotype-specific NAb and cellular immune response data have been published previously [22,24]. Here, we examined the NAb responses to HPV31, 33, 45, 52 and 58, six years after the last dose of 4vHPV and one month after a booster dose of 2vHPV.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules

et al. 2019

Self Cite

View full text Add to dashboard Cite

The duration of cross-neutralising antibody responses (cross-NAb) following HPV immunisation is unknown. We compared cross-NAb responses in cohort of girls who were either unimmunised or had received immunisation with one, two or three doses of 4vHPV (Gardasil®, Merck Inc., Kenilworth, NJ, USA) six years earlier, before and one month after a booster dose of 2vHPV (Cervarix®, GSK, Brentford, UK). NAb to potentially cross-reactive HPV genotypes 31, 33, 45, 52 and 58 were measured using a HPV pseudovirion-based neutralisation assay. Girls who had previously received at least one dose of 4vHPV had significantly higher NAb titres for HPV31 when compared with unimmunised girls, whereas no difference in NAb titre was observed for four other genotypes (33, 45, 52 and 58). Following a single further immunisation with 2vHPV, NAb titres to each of the five tested HPV genotypes were comparable for girls who previously received one, two or three doses of 4vHPV, and were significantly higher than for previously unimmunised girls. Immunisation with one, two or three doses of 4vHPV induced NAb to HPV31 that persisted for six years, but there was no persistence of NAb to HPV33, 45, 52 or 58. Our results suggest that one or two doses of 4vHPV may provide long-term protection against HPV31.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Study Design Procedures and Participantsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the overall population, the rate of anal infection by HPV-16/18 was lower (62%) [47]. Additionally, a randomized, double-blind, placebo-controlled clinical trial with more than 4,000 healthy men aged 16–26 years showed a significant reduction in the risk of external genital lesions (including condylomas) in the group receiving the 4-valent vaccine, with 90% efficacy in the HPV-naïve group and 65% in the overall population [48]. …”

Section: Data From Clinical Trialsmentioning

confidence: 99%

HPV Vaccine: Updates and Highlights

2019

View full text Add to dashboard Cite

HPV is the most common sexually transmitted biological agent and is the cause of many conditions in men and women, including precancer lesions and cancer. Three prophylactic HPV vaccines targeting high-risk HPV types are available in many countries worldwide: 2-, 4- and 9-valent vaccines. All the 3 vaccines use recombinant DNA technology and are prepared from the purified L1 protein that self-assembles to form HPV type-specific empty shells. This non-systematic review aims to summarize the HPV epidemiology and the vaccine development to review the landmark trials of HPV vaccine, to present to most remarkable results from clinical trials and the real world, and to stress the challenges and the barriers for HPV vaccine implementation.

show abstract

Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies

Quang,

Chung,

Kemp

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Neutralizing antibodies (NAbs) are considered the primary mechanism of vaccine‐mediated protection against human papillomaviruses (HPV), the causative agent of cervical cancer. However, the minimum level of NAb needed for protection is currently unknown. The HPV pseudovirion‐based neutralization assay (PBNA) is the gold standard method for assessing HPV antibody responses but is time‐consuming and labor‐intensive. With the development of higher valency HPV vaccines, alternative serological assays with the capacity for multiplexing would improve efficiency and output. Here we describe a multiplex bead‐based immunoassay to characterize the antibody responses to the seven oncogenic HPV types (HPV16/18/31/33/45/52/58) contained in the current licensed nonavalent HPV vaccine. This assay can measure antibody isotypes and subclasses (total IgG, IgM, IgA1–2, IgG1–4), and can be adapted to measure other antibody features (e.g., Fc receptors) that contribute to vaccine immunity. When tested with serum samples from unvaccinated and vaccinated individuals, we found high concordance between HPV‐specific IgG using this multiplex assay and NAbs measured with PBNA. Overall, this assay is high‐throughput, sample‐sparing, and time‐saving, providing an alternative to existing assays for the measurement and characterization of HPV antibody responses.

show abstract

Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study

Cited by 28 publications

References 30 publications

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules

HPV Vaccine: Updates and Highlights

Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies

Contact Info

Product

Resources

About